Tag

Drugs – canagliflozin

#281 ‒ Longevity drugs, aging biomarkers, and updated findings from the Interventions Testing Program (ITP) | Rich Miller, M.D., Ph.D.

What we try to do is quite simple. We try to find drugs that will slow aging and extend mouse lifespan.” —Rich Miller

#231 – AMA #41: Medicine 3.0, developments in the field of aging, healthy habits in times of stress, and more

“We have reached the limits of medicine 2.0 capacity, and if longevity is something we are aspiring for, we need a new strategy.” —Peter Attia

#171 – Steve Austad, Ph.D.: The landscape of longevity science: making sense of caloric restriction, biomarkers of aging, and possible geroprotective molecules

“I never thought [extending the human lifespan] was going to happen because we got better at treating cancer or we got better at preventing heart disease. I always thought it was going to happen because we would develop something … that would fundamentally change the rate of aging. And we haven’t developed that yet. We’ve got a lot of clues and I think we’re getting closer and closer and closer.” —Steve Austad

Are continuous glucose monitors a waste of time for people without diabetes?

Some experts suggest CGMs are useless for nondiabetics. I disagree.

#148 – Richard Miller, M.D., Ph.D.: The gold standard for testing longevity drugs: the Interventions Testing Program

“I don’t really care what causes aging. What I care about is: What is the process that can postpone all the different aspects of aging?” — Rich Miller

Facebook icon Twitter icon Instagram icon Pinterest icon Google+ icon YouTube icon LinkedIn icon Contact icon